# NCT04245670 (NCT04245670)

> 5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04245670
- Phase: NA
- Status: UNKNOWN
- Sponsor: Sunnybrook Health Sciences Centre
- Conditions: Prostate Cancer
- Interventions: Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5
- Enrollment: 75
- Primary outcome: Acute Toxicity
- Primary outcome: Acute Toxicity

## Indexed commentary on NCT04245670 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04245670